Pub Date : 2025-01-01DOI: 10.1016/j.eimce.2024.08.005
Maria Jose Muñoz Davila , Maria Teresa Cabezas Fernandez , Ana Belen Esteban García , Miguel José Martinez Lirola
{"title":"A simple MALDI–TOF-MS method for the identification of non-mycobacterial aerobic actinomycetes growing on blood agar subcultures from positive MGIT cultures","authors":"Maria Jose Muñoz Davila , Maria Teresa Cabezas Fernandez , Ana Belen Esteban García , Miguel José Martinez Lirola","doi":"10.1016/j.eimce.2024.08.005","DOIUrl":"10.1016/j.eimce.2024.08.005","url":null,"abstract":"","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":"43 1","pages":"Pages 55-57"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.eimce.2024.08.004
Idoia Bilbao , María Pascual , José Ramón Yuste , José Luis del Pozo
{"title":"Accidental intravenous probiotic injection in an immunocompromised patient: Implications and consequences","authors":"Idoia Bilbao , María Pascual , José Ramón Yuste , José Luis del Pozo","doi":"10.1016/j.eimce.2024.08.004","DOIUrl":"10.1016/j.eimce.2024.08.004","url":null,"abstract":"","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":"43 1","pages":"Pages 58-59"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.eimce.2024.07.007
Ángela Sánchez-Simarro , Eliseo Albert , Paula Michelena , Estela Giménez , David Navarro
Introduction
The extent to which commercially available nucleic acid extraction platforms impact the magnitude of Cytomegalovirus (CMV) DNA loads measured in plasma specimens by 1st WHO standard-normalized real-time PCR assays is uncertain.
Methods
This retrospective study compares the performance of Abbott m2000sp, Qiagen QIAsymphony SP, and KingFisher Flex platforms using plasma samples from allogeneic hematopoietic stem cell transplant recipients and plasma spiked with the CMV AD169 strain. The Abbott RealTime CMV PCR assay was used for CMV DNA quantitation.
Results
Maximum differences in CMV DNA loads quantified in plasma from 11 allo-HSCT and spiked plasma over a wide range of viral DNA concentrations (2.0–4.0 log10 IU/ml) were ≤0.5 log10 IU/ml.
Conclusions
The CMV DNA extraction efficiency of the platforms evaluated varies. The impact of these variations on CMV DNA loads quantified in plasma may not be clinically relevant.
{"title":"Impact of automated nucleic acid extraction platforms on plasma Cytomegalovirus DNA loads quantitated by real-time PCR normalized to the 1st WHO international standard","authors":"Ángela Sánchez-Simarro , Eliseo Albert , Paula Michelena , Estela Giménez , David Navarro","doi":"10.1016/j.eimce.2024.07.007","DOIUrl":"10.1016/j.eimce.2024.07.007","url":null,"abstract":"<div><h3>Introduction</h3><div>The extent to which commercially available nucleic acid extraction platforms impact the magnitude of Cytomegalovirus (CMV) DNA loads measured in plasma specimens by 1st WHO standard-normalized real-time PCR assays is uncertain.</div></div><div><h3>Methods</h3><div>This retrospective study compares the performance of Abbott m2000sp, Qiagen QIAsymphony SP, and KingFisher Flex platforms using plasma samples from allogeneic hematopoietic stem cell transplant recipients and plasma spiked with the CMV AD169 strain. The Abbott RealTi<em>m</em>e CMV PCR assay was used for CMV DNA quantitation.</div></div><div><h3>Results</h3><div>Maximum differences in CMV DNA loads quantified in plasma from 11 allo-HSCT and spiked plasma over a wide range of viral DNA concentrations (2.0–4.0 log<sub>10</sub> IU/ml) were ≤0.5 log<sub>10</sub> IU/ml.</div></div><div><h3>Conclusions</h3><div>The CMV DNA extraction efficiency of the platforms evaluated varies. The impact of these variations on CMV DNA loads quantified in plasma may not be clinically relevant.</div></div>","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":"43 1","pages":"Pages 28-31"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.eimce.2023.07.008
Carolina Duarte , Clara Inés Agudelo , Carlos Castañeda-Orjuela , Jaime Moreno , Olga Marina Sanabria , Adriana Bautista , Elizabeth Castañeda
Introduction
The introduction of pneumococcal conjugate vaccine (PCV) into childhood vaccination programmes has reduced the prevalence of vaccine serotypes (VTs) that cause invasive pneumococcal disease (IPD) in children. In the elderly population, an impact has also been seen through indirect protection (herd effect). The aim of this study was to estimate the changes in serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae isolates recovered from adult IPD and to evaluate the indirect effect of immunization with PCV10 based on laboratory records by analyzing the period from 2005 to 2019 for six years before and eight years after the universal PCV10 administration to Colombian children.
Methods
A total of 2204 S. pneumoniae isolates from adults (≥50 years) with IPD were analyzed. The analysis examined the percentage changes in proportions (prevalence) and percentage variations in population rates (annual reported rates – ARR) of VTs between the pre-PCV10 (2005–2009) and post-PCV10 (2015–2019) periods.
Results
The findings were (1) evidence of a significant percentage decrease of pneumococcal VT10 causing IPD in adults (50% pre-PCV10 and 16% post-PCV10); (2) significant increase of serotype 19A (from 1.6% to 14.8%) and less important increase of serotype 3 (from 10.5% to 14.5%) and non-vaccine serotypes (NVT) (from 21.4% to 38.4%) non-significant; and (3) meningitis and non-meningitis multidrug resistant isolates associated with serotype 19A. An improvement in the surveillance system is associated with the immunization of children, as noted by the increased ARRs across the analysis period.
Conclusions
Our results show the indirect impact of PCV10 vaccination in children on the VT10 distribution and antimicrobial resistance of S. pneumoniae causing IPD in Colombian adults over 50 when comparing the pre-PCV10 (2005–2009) and post-PCV10 (2015–2019) periods.
{"title":"Indirect impact of PCV10 children vaccination on the serotype distribution and antimicrobial resistance of Streptococcus pneumoniae causing invasive disease in adults over 50 in Colombia, 2005–2019: Observational analysis","authors":"Carolina Duarte , Clara Inés Agudelo , Carlos Castañeda-Orjuela , Jaime Moreno , Olga Marina Sanabria , Adriana Bautista , Elizabeth Castañeda","doi":"10.1016/j.eimce.2023.07.008","DOIUrl":"10.1016/j.eimce.2023.07.008","url":null,"abstract":"<div><h3>Introduction</h3><div><span>The introduction of pneumococcal conjugate vaccine (PCV) into childhood vaccination programmes has reduced the prevalence of vaccine serotypes (VTs) that cause invasive pneumococcal disease (IPD) in children. In the elderly population, an impact has also been seen through indirect protection (herd effect). The aim of this study was to estimate the changes in serotype distribution and antimicrobial susceptibility of </span><span><span>Streptococcus pneumoniae</span></span> isolates recovered from adult IPD and to evaluate the indirect effect of immunization with PCV10 based on laboratory records by analyzing the period from 2005 to 2019 for six years before and eight years after the universal PCV10 administration to Colombian children.</div></div><div><h3>Methods</h3><div>A total of 2204 <span><em>S. pneumoniae</em></span> isolates from adults (≥50 years) with IPD were analyzed. The analysis examined the percentage changes in proportions (prevalence) and percentage variations in population rates (annual reported rates – ARR) of VTs between the pre-PCV10 (2005–2009) and post-PCV10 (2015–2019) periods.</div></div><div><h3>Results</h3><div>The findings were (1) evidence of a significant percentage decrease of pneumococcal VT10 causing IPD in adults (50% pre-PCV10 and 16% post-PCV10); (2) significant increase of serotype 19A (from 1.6% to 14.8%) and less important increase of serotype 3 (from 10.5% to 14.5%) and non-vaccine serotypes (NVT) (from 21.4% to 38.4%) non-significant; and (3) meningitis and non-meningitis multidrug resistant isolates associated with serotype 19A. An improvement in the surveillance system is associated with the immunization of children, as noted by the increased ARRs across the analysis period.</div></div><div><h3>Conclusions</h3><div>Our results show the indirect impact of PCV10 vaccination in children on the VT10 distribution and antimicrobial resistance of <em>S. pneumoniae</em> causing IPD in Colombian adults over 50 when comparing the pre-PCV10 (2005–2009) and post-PCV10 (2015–2019) periods.</div></div>","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":"43 1","pages":"Pages 3-9"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72016341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Carbapenemase-producing Enterobacterales (CPE) is a global threat. We evaluate the prevalence of CPE among isolates categorized as meropenem-susceptible, but that meet the European Committee on Antimicrobial Susceptibility Testing (EUCAST) screening cut-off values for carbapenemase detection, and analyze the susceptibility of these isolates to new available drugs.
Methods
We analyzed 257 isolates from patients hospitalized in a tertiary hospital in Brazil, from July 2022 to April 2023. Only isolates that met the screening cut-off values established by EUCAST for detection of carbapenemases were analyzed (i.e. meropenem inhibition zones of 25–27 mm by disk diffusion). The detection of carbapenemases was performed by immnunochromatographic testing and confirmed by high-resolution melting-PCR (HRM-qPCR).
Results
We identified 12 (4.7%) CPE including 7 KPC, 4 NDM, and 1 OXA-48-like. The isolates were susceptible to ceftazidime–avibactam (72.7%), meropenem–vaborbactam (100%), imipenem–relebactam (63.6%) and ceftolozane–tazobactam (36.4%).
Conclusion
We highlight the importance of tracking carbapenemases for epidemiological control and therapeutic guidance.
{"title":"Detection of carbapenemases in Enterobacterales susceptible in vitro to meropenem","authors":"Luana Silva Dornelles , Mariana Preussler Mott , Gabriela da Silva Collar , Luciana Giordani , Rodrigo Minuto Paiva , Larissa Lutz","doi":"10.1016/j.eimce.2024.07.008","DOIUrl":"10.1016/j.eimce.2024.07.008","url":null,"abstract":"<div><h3>Introduction</h3><div>Carbapenemase-producing Enterobacterales (CPE) is a global threat. We evaluate the prevalence of CPE among isolates categorized as meropenem-susceptible, but that meet the European Committee on Antimicrobial Susceptibility Testing (EUCAST) screening cut-off values for carbapenemase detection, and analyze the susceptibility of these isolates to new available drugs.</div></div><div><h3>Methods</h3><div>We analyzed 257 isolates from patients hospitalized in a tertiary hospital in Brazil, from July 2022 to April 2023. Only isolates that met the screening cut-off values established by EUCAST for detection of carbapenemases were analyzed (i.e. meropenem inhibition zones of 25–27<!--> <!-->mm by disk diffusion). The detection of carbapenemases was performed by immnunochromatographic testing and confirmed by high-resolution melting-PCR (HRM-qPCR).</div></div><div><h3>Results</h3><div>We identified 12 (4.7%) CPE including 7 KPC, 4 NDM, and 1 OXA-48-like. The isolates were susceptible to ceftazidime–avibactam (72.7%), meropenem–vaborbactam (100%), imipenem–relebactam (63.6%) and ceftolozane–tazobactam (36.4%).</div></div><div><h3>Conclusion</h3><div>We highlight the importance of tracking carbapenemases for epidemiological control and therapeutic guidance.</div></div>","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":"43 1","pages":"Pages 32-35"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.eimce.2024.10.003
Ester Minguez de la Guía, Macarena López Vázquez, Pablo Miguel Valentín García, Miguel José Corbi Pascual
{"title":"Should we implant a pacemaker in a young patient with high-grade atrioventricular block? The importance of clinical suspicion in Lyme carditis","authors":"Ester Minguez de la Guía, Macarena López Vázquez, Pablo Miguel Valentín García, Miguel José Corbi Pascual","doi":"10.1016/j.eimce.2024.10.003","DOIUrl":"10.1016/j.eimce.2024.10.003","url":null,"abstract":"","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":"43 1","pages":"Pages 51-52"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142514088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.eimce.2023.12.004
Fares Amer , Fan-Yun Lan , Mario Gil-Conesa , Amalia Sidossis , Daniel Bruque , Eirini Iliaki , Jane Buley , Neetha Nathan , Lou Ann Bruno-Murtha , Silvia Carlos , Stefanos N. Kales , Alejandro Fernandez-Montero
Introduction
The COVID-19 pandemic caused by the SARS-CoV-2 virus greatly affected healthcare workers and healthcare systems. It also challenged schools and universities worldwide negatively affecting in-person education. We conducted this study is to assess the evolution of SARs-CoV-2 virulence over the course of the pandemic.
Methods
A combined cohort of University students in Spain and HCWs from the two hospitals in Spain, and one healthcare system in the Greater Boston area was followed prospectively from March 8th, 2020, to January 31st, 2022 for diagnosis with COVID-19 by PCR testing and related sequelae. Follow-up time was divided into four periods according to distinct waves of infection during the pandemic. Severity of COVID-19 was measured by case-hospitalization rate. Descriptive statistics and multivariable-adjusted statistics using the Poisson mixed-effects regression model were applied. As a sensitivity analysis, information on SARS-CoV-2 RNA in wastewater and COVID-19 deaths through May 30, 2023 from the Boston area was collected.
Results
For the last two periods of the study (January 1st to December 15th, 2021 and December 16th, 2021 to January 31st, 2022) and relative to the first period (March 8th to May 31st, 2020), the incidence rate ratios (IRRs) of hospitalization were 0.08 (95% CI, 0.03–0.17) and 0.03 (95% CI, 0.01–0.15), respectively. In addition, a relative risk 0.012 CI95% (0.012–0.012) was observed when comparing COVID-19 mortality versus SARS-CoV-2 RNA copies/mL in Boston-area wastewater over the period (16th December 2021 to 30th May 2023) and relative to the first period.
Conclusions
The severity of COVID-19 and immunity of our populations evolved over time, resulting in a decrease in case severity. We found the case-hospitalization rate decreased more than 90% in our cohort despite an increase in incidence.
{"title":"Evolving SARS-CoV-2 severity among hospital and university affiliates in Spain and Greater Boston","authors":"Fares Amer , Fan-Yun Lan , Mario Gil-Conesa , Amalia Sidossis , Daniel Bruque , Eirini Iliaki , Jane Buley , Neetha Nathan , Lou Ann Bruno-Murtha , Silvia Carlos , Stefanos N. Kales , Alejandro Fernandez-Montero","doi":"10.1016/j.eimce.2023.12.004","DOIUrl":"10.1016/j.eimce.2023.12.004","url":null,"abstract":"<div><h3>Introduction</h3><div>The COVID-19 pandemic caused by the SARS-CoV-2 virus greatly affected healthcare workers and healthcare systems. It also challenged schools and universities worldwide negatively affecting in-person education. We conducted this study is to assess the evolution of SARs-CoV-2 virulence over the course of the pandemic.</div></div><div><h3>Methods</h3><div>A combined cohort of University students in Spain and HCWs from the two hospitals in Spain, and one healthcare system in the Greater Boston area was followed prospectively from March 8th, 2020, to January 31st, 2022 for diagnosis with COVID-19 by PCR testing and related sequelae. Follow-up time was divided into four periods according to distinct waves of infection during the pandemic. Severity of COVID-19 was measured by case-hospitalization rate. Descriptive statistics and multivariable-adjusted statistics using the Poisson mixed-effects regression model were applied. As a sensitivity analysis, information on SARS-CoV-2 RNA in wastewater and COVID-19 deaths through May 30, 2023 from the Boston area was collected.</div></div><div><h3>Results</h3><div>For the last two periods of the study (January 1st to December 15th, 2021 and December 16th, 2021 to January 31st, 2022) and relative to the first period (March 8th to May 31st, 2020), the incidence rate ratios (IRRs) of hospitalization were 0.08 (95% CI, 0.03–0.17) and 0.03 (95% CI, 0.01–0.15), respectively. In addition, a relative risk 0.012 CI95% (0.012–0.012) was observed when comparing COVID-19 mortality versus SARS-CoV-2 RNA copies/mL in Boston-area wastewater over the period (16th December 2021 to 30th May 2023) and relative to the first period.</div></div><div><h3>Conclusions</h3><div>The severity of COVID-19 and immunity of our populations evolved over time, resulting in a decrease in case severity. We found the case-hospitalization rate decreased more than 90% in our cohort despite an increase in incidence.</div></div>","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":"43 1","pages":"Pages 17-22"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140875063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-30DOI: 10.1016/j.eimce.2024.12.002
Enrique Adolfo Orozco-Yee, Raquel Guadalupe Rojas-Castañeda, Elizabeth Guevara-Gutiérrez, Jorge Mayorga-Rodríguez, Alberto Tlacuilo-Parra
Background: Dermatophytosis caused by Nannizzia gypsea are considered rare. The clinical picture is indistinguishable from that produced by other dermatophytes, but, being this a geophilic fungus, it can cause more inflammatory disease.
Methods: Retrospective study. Patients with positive culture for N. gypsea observed at the Dermatological Institute of Jalisco "Dr. José Barba Rubio", from 2001 to 2023, were included. Frequency, sex, age, evolution, and clinical variant were investigated. We compared the findings between the pediatric versus adult population. Descriptive and inferential statistics were used.
Results: Over 23 years, 155 patients were diagnosed (6.7 cases per year). Female sex predominated (53.5%). The median age was 9 years (minimum 1year and maximum 85 years), the more affected age group was 1-10 years (54.2%). The median time of evolution was 30 days (minimum one day and maximum three years), and 74.8% had an evolution ≤30 days. Tinea capitis predominated in pediatric patients (41.0%, p<0.01) whereas tinea corporis predominated in adults (72.7%, p<0.01). Inflammatory tinea was more prevalent in the pediatric population (21.0% vs. 3.6%, p<0.01).
Conclusion: The ability of Nannizzia gypsea to cause inflammatory tinea was observed primarily in pediatric patients. Since there is no clinical data to suspect this fungus, it will always be necessary to carry out a mycological study to identify the species and to implement the appropriate treatment.
背景：由gypsea Nannizzia引起的皮肤真菌病被认为是罕见的。临床表现与其他皮肤真菌产生的症状难以区分，但是，由于这是一种嗜土真菌，它可以引起更多的炎症性疾病。方法：回顾性研究。纳入2001年至2023年在哈利斯科州皮肤病研究所“Dr. jos Barba Rubio”观察到的吉普赛奈瑟菌培养阳性患者。调查频率、性别、年龄、进化和临床变异。我们比较了儿童和成人的研究结果。采用描述性统计和推断性统计。结果：23年间确诊155例（6.7例/年）。女性占多数（53.5%）。中位年龄为9岁（最小1岁，最大85岁），发病最严重的年龄组为1-10岁（54.2%）。进化时间中位数为30天（最小1天，最大3年），74.8%的进化时间≤30天。结论：gypsea Nannizzia引起炎症性足癣的能力主要发生在儿科患者中。由于没有临床数据怀疑这种真菌，因此始终有必要进行真菌学研究以确定物种并实施适当的治疗。
{"title":"Dermatophytosis caused by Nannizzia gypsea: report of 155 cases from Western Mexico.","authors":"Enrique Adolfo Orozco-Yee, Raquel Guadalupe Rojas-Castañeda, Elizabeth Guevara-Gutiérrez, Jorge Mayorga-Rodríguez, Alberto Tlacuilo-Parra","doi":"10.1016/j.eimce.2024.12.002","DOIUrl":"https://doi.org/10.1016/j.eimce.2024.12.002","url":null,"abstract":"<p><strong>Background: </strong>Dermatophytosis caused by Nannizzia gypsea are considered rare. The clinical picture is indistinguishable from that produced by other dermatophytes, but, being this a geophilic fungus, it can cause more inflammatory disease.</p><p><strong>Methods: </strong>Retrospective study. Patients with positive culture for N. gypsea observed at the Dermatological Institute of Jalisco \"Dr. José Barba Rubio\", from 2001 to 2023, were included. Frequency, sex, age, evolution, and clinical variant were investigated. We compared the findings between the pediatric versus adult population. Descriptive and inferential statistics were used.</p><p><strong>Results: </strong>Over 23 years, 155 patients were diagnosed (6.7 cases per year). Female sex predominated (53.5%). The median age was 9 years (minimum 1year and maximum 85 years), the more affected age group was 1-10 years (54.2%). The median time of evolution was 30 days (minimum one day and maximum three years), and 74.8% had an evolution ≤30 days. Tinea capitis predominated in pediatric patients (41.0%, p<0.01) whereas tinea corporis predominated in adults (72.7%, p<0.01). Inflammatory tinea was more prevalent in the pediatric population (21.0% vs. 3.6%, p<0.01).</p><p><strong>Conclusion: </strong>The ability of Nannizzia gypsea to cause inflammatory tinea was observed primarily in pediatric patients. Since there is no clinical data to suspect this fungus, it will always be necessary to carry out a mycological study to identify the species and to implement the appropriate treatment.</p>","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-30DOI: 10.1016/j.eimce.2024.07.009
Blanca Carrasco, Elena Hidalgo, Gloria Zaragoza, Juan-Ignacio Alós
Introduction: For the microbiological diagnosis of bacteremia and fungemia, it is essential to use automated blood culture systems that guarantee good performance in the detection of microorganisms. We evaluated the BT24 system for blood cultures by comparing it with the BACTEC™ FX system in detection of positive spiked blood cultures (BC) and bottles, subsequent growth of the microorganism, and time to detection (TTD).
Methods: The parallel analysis of both systems was performed with 160 strains of 31 different species, each inoculated under the same conditions and simultaneously in six blood culture bottles. The Chi-square test was used for comparison per BC and per bottle detection. Wilconxon test and Student's t-test were used for comparison of TTDs.
Results: Overall, the following BC (aerobic bottle+anaerobic bottle) were detected as positive: 160/160 (100%) in BACTEC FX and 158/160 (98.7%) in BT24 (P=.31). Furthermore, the following pediatric blood cultures (1 single bottle, aerobic) were also detected: 159/160 (99.4%) in BACTEC FX and 156/160 (97.5%) in BT24 (P=.17). TTDs were longer with BT24 system than with BACTEC FX system, especially for Staphylococcus aureus strains.
Conclusions: We consider the BT24 system with good performance and specificity comparable to the reference system, but inferior in TTD.
{"title":"Evaluation of Zhuhai DL Biotech's BT24 automated blood culture system.","authors":"Blanca Carrasco, Elena Hidalgo, Gloria Zaragoza, Juan-Ignacio Alós","doi":"10.1016/j.eimce.2024.07.009","DOIUrl":"https://doi.org/10.1016/j.eimce.2024.07.009","url":null,"abstract":"<p><strong>Introduction: </strong>For the microbiological diagnosis of bacteremia and fungemia, it is essential to use automated blood culture systems that guarantee good performance in the detection of microorganisms. We evaluated the BT24 system for blood cultures by comparing it with the BACTEC™ FX system in detection of positive spiked blood cultures (BC) and bottles, subsequent growth of the microorganism, and time to detection (TTD).</p><p><strong>Methods: </strong>The parallel analysis of both systems was performed with 160 strains of 31 different species, each inoculated under the same conditions and simultaneously in six blood culture bottles. The Chi-square test was used for comparison per BC and per bottle detection. Wilconxon test and Student's t-test were used for comparison of TTDs.</p><p><strong>Results: </strong>Overall, the following BC (aerobic bottle+anaerobic bottle) were detected as positive: 160/160 (100%) in BACTEC FX and 158/160 (98.7%) in BT24 (P=.31). Furthermore, the following pediatric blood cultures (1 single bottle, aerobic) were also detected: 159/160 (99.4%) in BACTEC FX and 156/160 (97.5%) in BT24 (P=.17). TTDs were longer with BT24 system than with BACTEC FX system, especially for Staphylococcus aureus strains.</p><p><strong>Conclusions: </strong>We consider the BT24 system with good performance and specificity comparable to the reference system, but inferior in TTD.</p>","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-30DOI: 10.1016/j.eimce.2024.12.003
Vicente Estrada, Juan Emilio Losa, Ramón Morillo-Verdugo, Montserrat Pérez-Encinas, Jesús Santos, Antonio Castro, María Presa González, Laura Salinas-Ortega
Objetive: To identify and analyze the resources and costs associated with the administration of intramuscular antiretroviral therapy (ART) cabotegravir+rilpivirine (CAB+RPV) compared to oral ART in the management of Human Immunodeficiency Virus Type 1 (HIV-1) infection in Spain.
Methods: An economic model was developed to identify resources and analyze costs from the perspective of the National Health System (NHS) and societal, associated with the administration of intramuscular ART (CAB+RPV) compared to oral ART over a two-year time horizon. Costs included treatment change monitoring, pharmaceutical dispensation, administration, management of adverse events to injection-site reactions (AEs-ISR), travel to the hospital, telepharmacy service, and lost work productivity. Unit costs (€, 2023) were obtained from the literature. Sensitivity analyses were conducted to evaluate the robustness of the model.
Results: Intramuscular ART compared to oral ART was associated with an increase in costs of €673.16/patient over two years from the perspective of the NHS, and €719.59/patient from the social perspective. Intramuscular ART would generate increased costs for dispensation (+€97.75), administration (+€394.55), monitoring (+€288.74), management of AEs-ISR (+€6.46), travel (+€8.36), and lost work productivity (+€38.07), compared to oral ART administration.
Conclusion: Treating HIV-1 with intramuscular CAB+RPV leads to increased resource consumption and costs, compared to oral ART.
{"title":"Cost analysis associated with intramuscular versus oral administration of antiretroviral therapy in the management of human immunodeficiency virus infection.","authors":"Vicente Estrada, Juan Emilio Losa, Ramón Morillo-Verdugo, Montserrat Pérez-Encinas, Jesús Santos, Antonio Castro, María Presa González, Laura Salinas-Ortega","doi":"10.1016/j.eimce.2024.12.003","DOIUrl":"https://doi.org/10.1016/j.eimce.2024.12.003","url":null,"abstract":"<p><strong>Objetive: </strong>To identify and analyze the resources and costs associated with the administration of intramuscular antiretroviral therapy (ART) cabotegravir+rilpivirine (CAB+RPV) compared to oral ART in the management of Human Immunodeficiency Virus Type 1 (HIV-1) infection in Spain.</p><p><strong>Methods: </strong>An economic model was developed to identify resources and analyze costs from the perspective of the National Health System (NHS) and societal, associated with the administration of intramuscular ART (CAB+RPV) compared to oral ART over a two-year time horizon. Costs included treatment change monitoring, pharmaceutical dispensation, administration, management of adverse events to injection-site reactions (AEs-ISR), travel to the hospital, telepharmacy service, and lost work productivity. Unit costs (€, 2023) were obtained from the literature. Sensitivity analyses were conducted to evaluate the robustness of the model.</p><p><strong>Results: </strong>Intramuscular ART compared to oral ART was associated with an increase in costs of €673.16/patient over two years from the perspective of the NHS, and €719.59/patient from the social perspective. Intramuscular ART would generate increased costs for dispensation (+€97.75), administration (+€394.55), monitoring (+€288.74), management of AEs-ISR (+€6.46), travel (+€8.36), and lost work productivity (+€38.07), compared to oral ART administration.</p><p><strong>Conclusion: </strong>Treating HIV-1 with intramuscular CAB+RPV leads to increased resource consumption and costs, compared to oral ART.</p>","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号